<DOC>
	<DOCNO>NCT01305135</DOCNO>
	<brief_summary>Patients receive escalate dos ldarubicin combine Azacitidine give FDA/EMEA approve Schedule dose . For Phase I study : Determine safety tolerance escalate dos Idarubicin combine Azacitidine patient INT-2 high risk MDS . For phase II study : Primary : Evaluate rate duration response ( accord IWG 2006 criterion IWG 2000 criterion ) combination Idarubicin Azacitidine patient INT-2 high risk MDS</brief_summary>
	<brief_title>Idarubicin Combined Azacitidine Int-2 High Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description>Patients receive ldarubicin combine Azacitidine . - The first 10 patient receive Idarubicin 5 mg/m2/d day 8 cycle Azacitidine 75 mg/m2/d CI 7 day ( First Cohort ) . - Progression next cohort 10 patient : Idarubicin 10 mgm2/d day 8 cycle Azacitidine 75 mg/m2/d CI 7 day ( Second cohort 10 patient ) , decide completion first cohort , review hematological toxicity independent safety review committee ( SRC ) . - The next 21 patient treat either accord first second cohort schedule Idarubicin , review hematological toxicity efficacy independent safety review committee ( SRC ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Documented diagnosis MDS , CMML WBC &lt; 13,000/mm3 meet IPSS criterion intermediate2 highrisk disease , IPSS score ≥1.5 Myocardial function contraindicate use idarubicin Age ≥ 18 year Performance Status ≤2 accord ECOG . Serum creatinine &lt; 1.5 x ULN normal level electrolyte ( serum sodium 136145 mmol/l , Potassium 3,54,5 mmol/l , alkaline Reserve 2329 mmol/l , , Calcium 2,152,5 mmol/l , Phosphore 0,871,45 mmol/l ) Serum aspartate aminotransferase ( AST ) /serum glutamicoxaloacetic transaminase ( SGOT ) alanine transaminase ( ALT ) /serum glutamate pyruvate transaminase ( SGPT ) &lt; 1.5 x upper limit normal ( ULN ) Serum total bilirubin &lt; 1.5 x ULN . Must able adhere study visit schedule protocol requirement Signed informed consent . Female subject childbearing potential must : • Accept effective contraception without interruption throughout duration study three month end treatment . Male subject must Agree use condom throughout study drug therapy , dose interruption one week cessation study therapy three month final treatment partner childbearing potential contraception . Agree learn procedure preservation sperm Uncontrolled infection Prior therapy anthracycline MDS . Eligible allogeneic stem cell transplantation . Prior therapy demethylating agent within last 3 month Prior therapy Hematopoietic growth factor ( ESA GCSF ) agent cytotoxic agent ( oral chemotherapy , low dos AraC ) within last 30 day . Prior history malignancy MDS ( except basal cell squamous cell carcinoma carcinoma situ cervix breast ) Pregnant lactate female Known HIV1 positivity Contraindication Anthracyclines</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>myelodysplastic syndrome , azacitidine , idarubicin</keyword>
</DOC>